文献速递肺结节与肺癌

度伐利尤单抗联合卡铂依托泊苷治疗体能状态差的广泛期小细胞肺癌:NEJ045A单臂2期试验

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial.
PubMed 文献 · Lancet Respir Med · 2025-09-28

NEJ045A单臂2期试验评估度伐利尤单抗联合卡铂依托泊苷一线治疗体能状态2或3的初治广泛期小细胞肺癌患者,主要终点为诱导治疗完成率。

要点

  • 体能状态2患者诱导完成率67%,体能状态3患者50%,均超过预设阈值。
  • ≥3级不良事件发生率93%,21%患者因不良事件停药。

核心结论

  • 度伐利尤单抗联合卡铂依托泊苷对体能状态差的初治广泛期小细胞肺癌显示出耐受性和有前景的疗效。

研究设计与样本

  • 开放标签、单臂2期NEJ045A试验,纳入57例体能状态2或3的初治广泛期小细胞肺癌患者。
  • 患者接受4周期度伐利尤单抗联合卡铂依托泊苷,后续度伐利尤单抗维持治疗,采用剂量调整策略。
  • 主要终点为耐受性,以完成诱导治疗的患者比例评估;关键次要终点为1年生存率。

主要发现

  • 56例可评估患者中52例(93%)发生≥3级不良事件,12例(21%)因不良事件中止治疗。

关键数值与推荐

  • 诱导治疗完成率预设阈值未在摘要中报告。
  • 剂量调整策略:初始降低卡铂依托泊苷剂量,后续根据不良事件调整,允许剂量递增。

临床怎么用

  • 对于体能状态差的初治广泛期小细胞肺癌患者,可考虑度伐利尤单抗联合卡铂依托泊苷作为一线治疗选择。
  • 治疗中需密切监测不良事件,并按方案进行剂量调整。

局限性

  • 单臂设计,无对照组,样本量较小(57例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treating patients with extensive-stage small-cell lung cancer (SCLC) with poor performance status poses considerable challenges. We aimed to evaluate the combination of an immune checkpoint inhibitor with platinum-based therapy in this population. METHODS: This open-label, single-arm phase 2 NEJ045A trial enrolled untreated patients with extensive-stage SCLC with performance status 2 or 3. Participants received four cycles of durvalumab, carboplatin, and etoposide, followed by durvalumab maintenance. A dose adjustment strategy was used, with initial reductions in carboplatin-etoposide dosages, subsequently adjusted based on adverse events, allowing for potential escalation. The primary endpoint was tolerability, assessed by the proportion of patients completing induction therapy. A key secondary endpoint was 1-year survival rate. This trial is registered at the Japan Registry of Clinical Trials (jRCTs031200319) and has been completed. FINDINGS: Between April 8, 2021, and Oct 3, 2023, 57 patients (performance status 2 n=43 and performance status 3 n=14) were enrolled with a median age of 73·5 years (IQR 69·0-77·5), 44 (79%) of 56 were male. 26 (67%; 80% CI 55·2-76·7; p<0·0001) of 39 patients with performance status 2 and five (50%; 26·7-73·3; p=0·0088) of ten with performance status 3 completed induction therapy, exceeding the pre-specified threshold. Grade 3 or higher adverse events occurred in 52 (93%) of 56 patients, and 12 (21%) of 56 discontinued due to adverse events. The 1-year survival rates were 43·4% (80% CI 34·1-53·1) overall (p<0·0001), 50·0% (39·1-60·9) in performance status 2 (p<0·0001), and 18·2% (5·0-41·5) in performance status 3. INTERPRETATION: Durvalumab, carboplatin, and etoposide showed tolerability and promising efficacy as a first-line treatment for patients with untreated extensive-stage SCLC with poor performance status, supporting the integration of immune checkpoint inhibitors in this therapeutically challenging population. FUNDING: AstraZeneca KK.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Asao T, Saida Y, Watanabe S, et al. Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial. Lancet Respir Med. 2025. PMID: 41033335. doi:10.1016/S2213-2600(25)00240-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。